Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HN2302 in Autoimmune Diseases
NCT07523282Phase 1Not yet recruiting
- Sponsor
- Shenzhen MagicRNA Biotechnology
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HN2302 in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), sponsored by Shenzhen MagicRNA Biotechnology. Primary endpoint: Incidence of treatment-emergent adverse events at 3 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
HN2302
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07523282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523282.